FGFR1 amplification was found to promote the resistance of luminal B type breast cancer to hydroxytamoxifen, whereas inhibition of FGF-signaling by siFGFR1 abrogated this resistance [40]. The gene discussed is FGFR1; the disease is breast carcinoma.